spacer
home > ict > spring 2017 > on the lake
PAY PER VIEW SERVICE

 

Dear guest!

article: On the Lake
format: Adobe Acrobat PDF file
cost: £

spacer

 
News and Press Releases

European Commission Approves BYANNLIŽ (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLIŽ (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement